A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

BACKGROUND: Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study aimed to evaluate the efficacy and safety of hetrombopag in ITP patients. METHO...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Hematol Oncol
Autori principali: Mei, Heng, Liu, Xiaofan, Li, Yan, Zhou, Hu, Feng, Ying, Gao, Guangxun, Cheng, Peng, Huang, Ruibin, Yang, Linhua, Hu, Jianda, Hou, Ming, Yao, Yazhou, Liu, Li, Wang, Yi, Wu, Depei, Zhang, Liansheng, Zheng, Changcheng, Shen, Xuliang, Hu, Qi, Liu, Jing, Jin, Jie, Luo, Jianmin, Zeng, Yun, Gao, Sujun, Zhang, Xiaohui, Zhou, Xin, Shi, Qingzhi, Xia, Ruixiang, Xie, Xiaobao, Jiang, Zhongxing, Gao, Li, Bai, Yuansong, Xiong, Junye, Li, Runzi, Zou, Jianjun, Niu, Ting, Yang, Renchi, Hu, Yu
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2021
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7905908/
https://ncbi.nlm.nih.gov/pubmed/33632264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01047-9
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi